NCT03748641 2026-03-16
MAGNITUDE
Janssen Research & Development, LLC
Phase 3 Active not recruiting
Clinical Trials
13 trialsNCT05968599 2026-02-25
A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer
Pfizer
Completed
NCT05551117 2026-02-09
Tamarack
MacroGenics
Phase 2 Terminated
NCT03431350 2025-12-23
QUEST
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT02204072 2025-07-15
BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)
Boehringer Ingelheim
Phase 1 Completed
NCT03822845 2025-04-17
Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer
University of Iowa
Phase 2/3 Completed
NCT03248570 2024-11-20
Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects
University of California, San Francisco
Phase 2 Completed
NCT05520138 2024-09-27
Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)
Pfizer
Completed
NCT03016312 2024-08-09
IMbassador250
Hoffmann-La Roche
Phase 3 Completed
NCT03389451 2024-07-12
68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer
University of Iowa
Phase 2/3 Completed
NCT03388346 2024-02-15
68Ga PSMA in Preprostatectomy Patients
University of Iowa
Phase 2/3 Completed
NCT04157088 2023-08-04
DaroAcT
Bayer
Phase 2 Terminated
NCT02057666 2021-04-23
TasQ003
Ipsen
Phase 3 Terminated